Trial Profile
REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms REFINE
- Sponsors Bayer
- 20 Jan 2024 Results of subgroup analysis of patients with unresectable hepatocellular carcinoma and Child-Pugh-B liver function treated with regorafenib in routine clinical practice presented at the 2024 Gastrointestinal Cancers Symposium.
- 24 Oct 2023 Final analysis (n=1005) of this study confirming the safety and effectiveness of regorafenib (REG) in patients prior liver transplantation (PLT) with unresectable hepatocellular carcinoma (uHCC) presented at the 48th European Society for Medical Oncology Congress.
- 12 Oct 2023 According to a Bayer media release, the company will highlight data from this study will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress taking place in Madrid, Spain from October 20-24, 2023.